title: Regulation of leptin distribution between plasma and cerebrospinal fluid by cholecystokinin receptors.
abstract: Cholecystokinin (CCK) is a postprandial hormone that elicits a satiating effect and regulates feeding behaviour. CCK has been shown to enhance the effect of leptin in several experimental paradigms. The goal of this work was to characterize the effect of endogenous CCK on plasma leptin content by using CCK receptor antagonists. Therefore, we administered SR-27897, a selective CCK1 receptor antagonist, and L-365260, a selective CCK2 receptor antagonist, to fed and food-deprived rats and determined plasma leptin concentration by enzyme immunoassay. Plasma insulin and glucose concentration as well as food intake were also determined. Under our conditions, SR-27897 increased plasma concentration of leptin both in fed and food-deprived rats. It also increased food intake as well as plasma concentration of insulin in fed animals. L-365260 increased plasma leptin concentration only in fed rats. In animals receiving exogenous leptin, CCK-8 increased the ratio between the concentration of leptin in cerebrospinal fluid and plasma. These results show that CCK receptor antagonists increases plasma concentration of leptin and suggest that endogenous CCK may facilitate the uptake of plasma leptin to the cerebrospinal fluid.
authors.affiliation: Departamento de Farmacología, Tecnología y Desarrollo Farmacéutico, Universidad San Pablo-CEU, Urbanización Montepríncipe, Boadilla del Monte, Madrid 28668, Spain.
authors.forename: Victoria
authors.initials: V
authors.lastname: Cano
authors.forename: Laura
authors.initials: L
authors.lastname: Ezquerra
authors.forename: M Pilar
authors.initials: MP
authors.lastname: Ramos
authors.forename: Mariano
authors.initials: M
authors.lastname: Ruiz-Gayo
mesh_terms: D000818:Animals; D001570:Benzodiazepinones / Q000008:administration & dosage / Q000493:pharmacokinetics; D001786:Blood Glucose / Q000187:drug effects; D002766:Cholecystokinin / Q000037:antagonists & inhibitors / Q000502:physiology; D004435:Eating / Q000187:drug effects / Q000502:physiology; D005215:Fasting / Q000502:physiology; D007210:Indoleacetic Acids / Q000008:administration & dosage / Q000493:pharmacokinetics; D007274:Injections, Intraperitoneal; D007279:Injections, Subcutaneous; D007328:Insulin / Q000097:blood; D020738:Leptin / Q000097:blood / Q000134:cerebrospinal fluid / Q000378:metabolism*; D008297:Male; D010671:Phenylurea Compounds / Q000008:administration & dosage / Q000493:pharmacokinetics; D051381:Rats; D017208:Rats, Wistar; D011949:Receptors, Cholecystokinin / Q000037:antagonists & inhibitors / Q000187:drug effects / Q000502:physiology*; D013844:Thiazoles / Q000008:administration & dosage / Q000493:pharmacokinetics; D014018:Tissue Distribution / Q000187:drug effects
chemical_list: D001570:Benzodiazepinones; D001786:Blood Glucose; D007210:Indoleacetic Acids; D007328:Insulin; D020738:Leptin; D010671:Phenylurea Compounds; D011949:Receptors, Cholecystokinin; D013844:Thiazoles; C080460:SR 27897; C058121:L 365260; D002766:Cholecystokinin